Forward looking statement

This document has been prepared by Genomic Vision (the "Company") and is provided for information purposes only. This document does not purport to contain comprehensive or complete information about the Company and is qualified in its entirety by the business, financial and other information that the Company is required to publish in accordance with the rules, regulations and practices applicable to companies listed on Euronext Paris. No reliance may be placed for any purposes whatsoever on the information or opinions contained in this document or on its accuracy or completeness This presentation does not constitute an offer to sell, a solicitation of, or an invitation to subscribe for or to buy, securities of Genomic Vision in any jurisdiction.

The information and opinions contained in this document are provided as of the date of this document only and may be updated, supplemented, revised, verified or amended, and thus such information may be subject to significant changes. The Company is not under any obligation to update the information or opinions contained herein which are subject to change without prior notice.

The information contained in this document has not been subject to independent verification. No representation, warranty or undertaking, express or implied, is made as to the accuracy, completeness or appropriateness of the information and opinions contained in this document. The Company, its subsidiaries, its advisors and representatives accept no responsibility for and shall not, under any circumstance, be held liable for any loss or damage that may arise from the use of this document or the information or opinions contained herein.

This document contains information on the Company's markets and competitive position, and more specifically, on the size of its markets. This information has been drawn from various sources or from the Company's own estimates which may not be accurate and thus no reliance should be placed on such information.

This document contains certain forward-looking statements. These statements are not guarantees of the Company's future performance. These forward-looking statements relate to the Company's future prospects, developments and marketing strategy and are based on analyses of earnings forecasts and estimates of amounts not yet determinable. Forward-looking statements are subject to a variety of risks and uncertainties as they relate to future events and are dependent on circumstances that may or may not materialize in the future. Forward-looking statements cannot, under any circumstance, be construed as a guarantee of the Company's future performance and the Company's actual financial position, results and cash flow, as well as the trends in the sector in which the Company operates, may differ materially from those proposed or reflected in the forward-looking statements contained in this document. Important factors that could cause actual results to differ materially from the results anticipated in the forward looking statements include those discussed or identified in the "Risk Factors" section of our Base Document registered with the Autorité des marchés financiers on March 3, 2014 under number I.14-005 (a copy of which is available on www.genomicvision.com). Even if the Company's financial position, results, cash-flows and developments in the sector in which the Company operates were to conform to the forward-looking statements contained in this document, such results or developments cannot be construed as a reliable indication of the Company's future results or developments. The Company does not undertake any obligation to update or to confirm projections or estimates made by analysts or to make public any correction to any prospective information in order to reflect an event or circumstance that may occur after the date of this document. Certain figures and numbers appearing in this document have been rounded. Consequently, the total amounts and percentages appearing in the tables may not necessarily equal the sum of the individually rounded figures, amounts or percentages. All persons accessing this document must agree to the restrictions and limitations set out above.
Genomic Vision at a glance

• **Commercial-stage Molecular DX company** developing and selling tests and assays on **Molecular Combing platform** for:
  - In Vitro diagnostics (IVD) for genetic diseases and cancers
  - Life Sciences Research (LSR)

• **Proprietary technology enabling direct visualization of high molecular weight DNA molecules**
  Unique position to address both:
  - Structural Genomics (GMC)
  - Functional Genomics: DNA replication

• **Multiple value-creation milestones:**
  - Promising pipelines in IVD (HPV, SMA)
  - Adoption of Replicome in Pharma especially for novel therapeutic discovery & development in immuno-oncology
  - Novel tool for Gene Engineering optimization and safety tool
From breakthrough innovation to commercialization

14 patented portfolios
2 co-patented portfolios
6 patented portfolios licensed from Pasteur

- Co-development agreement with the Assistance Publique - Hôpitaux de Marseille
  2006
- Strategic alliance with Quest Diagnostics
  2010
- CombHeliX FSHD test CE marked
  2013
- CombHeliX FSHD test commercialized in US and EU
  2015
- Renewal of alliance with QD until 2018
  2015
- IPO on Euronext Paris, €25.8m raised
  2014
- Product & Services Offering for LSR market
  2016
- Technological collaboration with AstraZeneca
  2017

Company was created as a spin-off from Institut Pasteur
2004

14 patented portfolios
2 co-patented portfolios
6 patented portfolios licensed from Pasteur

GENOMIC VISION
INSTITUT PASTEUR
Company was created as a spin-off from Institut Pasteur
2004

14 patented portfolios
2 co-patented portfolios
6 patented portfolios licensed from Pasteur

Technological collaboration with AstraZeneca
2017
Direct visualization of high molecular weight DNA molecules

The process of stretching DNA on a substrate by the action of an air/liquid interface

- No prior amplification
- Uniform and constant stretching factor (2kb=1µm), irrespective of DNA molecule size
- Stretching independent of sequence content
- Hundreds of copies of a diploid human genome stretched on one surface

DNA combing automatized with GV equipment FiberComb
Direct visualization of 3kbp–1Mbp DNA

NGS (Sequencing) misses Structural Variations (SV) that drive biology and pathology.

GV unique technology enables to visualize Structural Variations and dynamic genomic events (Copy Number Variations).
GV is well positioned in the Structural Variations and Copy Number Variations segments, with a relatively low number of competitors.
Workflow and Product offering (sales & services)

1. Extraction
   - FiberPrep® DNA Extraction Kit

2. Combing
   - FiberComb® Molecular Combing System

3. Hybridisation / Label Detection
   - FiberProbes® Genomic Morse Code set

4. Image acquisition
   - FiberVision® Automated high throughput Scanner

5. GMC analysis
   - FiberStudio® Analysis Software Report

In progress in 2017 development of new products offering
GV’s products & services address the life science continuum

Academic research

Drug Discovery

Gene Editing

Clinical Diagnostics

Life Sciences Research (LSR)

In Vitro Diagnostic (IVD)

Biopharma, Industry, Academic labs

Hospitals, Reference labs

**Products & Services**

- Research tools with combing
- Discovery tool, biomarkers identification
- DNA replication, damage and repair assays

**Products**

- Genetic testing for hereditary diseases and cancers:
  - Diagnostic
  - Predisposition
  - Carrier screening
  - Screening
Diversified assay pipeline with near-term value creation

**Life Sciences Tools (LST)**
- **Product design**: RCA
- **Product development**: GMC
- **Research lab collaboration**: GE
- **Industrialization Commercial launch**: 2016

**In Vitro Diagnostic (IVD)**
- **Identification of targets/gene biomarkers**: FSHD, BRCA, HNPCC
- **Development**: SMA
- **Clinical evaluation**: HPV*
- **Commercial launch**: 2013

Additional information:
- *Screening test not covered by North America exclusivity rights granted to Quest Diagnostic
- Biomarker validation expected in 2017
A novel tool for measuring DNA dynamics
Technical added-value & robustness of GV technology

• Immocytochemistry
  - Global average analysis

• Fiber Spreading
  - Discrete counting of molecular events
  - Approximate measurement of events

• Molecular Combing
  - Discrete counting of molecular events
  - Reliable measurement of kinetics
  - High sensitivity

*Svetlova et al., Experimental Cell Research 276, (2002) – **MRC LMB Lab website (UK)
A novel tool for measuring DNA dynamics

Replication and Repair assays

- Precise measurement of DNA replication kinetics, origin counting
- Evaluation of repair capacity (NER system)
  - Fundamental studies, knock-out models, drug development, therapy response, genotoxicity
A novel tool for Genome Editing

Tailor-made GMC provides a powerful quality control tool for high-confidence gene editing

- **Validate** the planned gene editing event – deletion, insertion
- **Detect** incorrect events larger than 1kb – incorrect deletion, insertion, inversion
- **Quantify** Off-target / On-target Ratio

**Normal signals**  
[No deletion]

**Gene-edited signals**  
[Deletion]
Replication kinetics
- Unique technology enabling to analyze replication kinetics of molecules
- Potential for discovery of novel drug

Safety tool
- Enabling to check by high sensitivity & unbiased direct visualization:
  - On-target stability
  - Rare off-target translocation

Emerging markets at the heart of the future precision medicine

Astra Zeneca
- Technological collaboration in the field of targeting DNA damage response (DDR) for novel anti-cancer treatments strategy.
- Initiated in Q2’17 with platform installed at AZ Cambridge Genetic Center
- Under exploration
Commercial strategy in Life Sciences Research

Key Partnerships & Targeted Commercial Deals

Feed Product Innovation

Generate Opportunities

Hardware/Software

FiberComb®
FiberVision®
FiberStudio®

Consumables

FiberPrep®
Accessories
FiberProbes®

Services

GMC On Demand

EasyScan

R&D services

Customer support

LeLab
SMA combing test: improvement of the genetic counselling by identifying a sub-population of SMA carriers

Spinal Muscular Atrophy

- Autosomal recessive disorder due to homozygous loss of functional SMN1 protein
- 1 million to 1.5 million healthy carriers in Franc, 8% of them going undetected by tests currently available
- 2nd most frequent neuromuscular child disease after Duchenne with incidence of 1/6,000 - 1/10,000 births

Genomic Vision’s objectives:

- Identification by Molecular Combing of a biomarker associated with the “2+0” structural variation
- Development of a clinical diagnostics test to identify “2+0” carriers

International partnerships and entry into clinical development

- The SMN locus, poorly characterized by sequencing, was precisely mapped by molecular combing
- BADGES study (NCT02550691) in collaboration with the Rouen University Hospital
- A Pilot study with Quest Diagnostics with samples from African-American cohort
- Participation in ‘BeyondSeq’, a European’s Commission project within the framework of the Horizon 2020 program
HPV combing test: a “game changer” and unpartnered asset

Cervical cancer

- Cervical cancer is the third most common cancer among women
- Almost 100% of patients with cervical cancer are positive for HPV
- 90% are transient, the persistence is usually accompanied by the integration of the HPV

<table>
<thead>
<tr>
<th>ROUTINE PAP-SMEAR</th>
<th>ESTIMATED SCREENING MARKET</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ambiguous results</td>
<td>HPV tests</td>
</tr>
<tr>
<td>Clear cut results</td>
<td>56.3 million</td>
</tr>
<tr>
<td>HPV Test</td>
<td>67.5 million</td>
</tr>
<tr>
<td>HPV + 50%</td>
<td>Nb. of colposcopies per year</td>
</tr>
<tr>
<td>HPV Combing Test</td>
<td>3.4 million</td>
</tr>
<tr>
<td>Pos</td>
<td>4.1 million</td>
</tr>
</tbody>
</table>

50% of women tested positive with a conventional HPV test do not require colposcopy

HPV Combing test to avoid invasive and expensive colposcopies

- Detection of HPV integration
- Distinguishes high-or low-risk patients
- Avoids useless invasive colposcopies

HPV clinical study underway

- Clinical study started at Reims University Hospital to Establish New Screening Tool for Early Detection and Prevention of Cervical Cancer
- In parallel, Clinical study on-going in Prague with PCS CRO: interim promising results disclosed in May 2017
Brca Combing Test: A Potential Blockbuster for Brca Large Rearrangements Detection

Hereditary Breast and Ovarian Cancer (HBOC)

- 5% - 10% of breast cancer cases are familial inherited
- HBOC risk increases dramatically in the presence of mutations in Brca1 and Brca 2 genes
- 10% - 15% of Brca mutations are Large Rearrangements (LR)

Brca Combing Test Enables Detecting New LR in Brca Genes

Brca Combing Test Added Values:
- Detection of all balanced rearrangements
- Covers exon and non-coding regions
- Accurate visualization hard to sequence regions

Test Development On-going

- Test validation by quest diagnostics in 2015
- Clinical utility and positioning study in europe and the USA to support marketing and reimbursement of the test ongoing (Brca1000 study jointly performed with quest diagnostics)
Strategic U.S. partnership with Quest Diagnostics

**Description partnership**

1. **Initial R&D funding**
   - Payment to GV of R&D milestones
   - Development of lab-developed tests (LDTs) used by Quest

2. **Commercial license**
   - An exclusive license for commercializing in the US:
     - FSHD test: launched in August 2013
     - BRCA test (clinical study ongoing)
     - HNPCC test (pending QD)
     - SMA (clinical study to be completed in 2018)
   - High teens royalties

**Quest’s Background**

- US leading provider in clinical diagnostic (24% market share)
- Annual revenues of approx. $7,5 billion

3. **Equity investment**
   - 13.8% stake in Genomic Vision
   - 1 Board member

- Strategic alliance with Quest Diagnostic since 2010, renewed in 2015 for 3 additional years until November 2018
- Strong interest expressed by Quest Diagnostics management for the unique combing platform developed by GV to enable discovering new products and offering better services to patients

- Strong interest expressed by Quest Diagnostics management for the unique combing platform developed by GV to enable discovering new products and offering better services to patients
Academic Combing Community Collaborations expansion

Example of Key Academics using GV combing technology (non-exhaustive):

Increasing adoption of combing: 112 FiberComb installed base in 2016
Expanded commercial footprint

- Global Pharma and Gene Editing collaborations
- LSR Direct sales force (US & Europe) and distribution contract established for China
- IVD strategic partnership in the US with Quest Diagnostics
- e-Commerce Web site launch in Q2 2017
2017 business update and outlook
GV Business Model: multiple revenue streams

- Hardware & software sales
  - FiberComb®
  - FiberVision®

- Consumable sales
  - Combicoverslips®
  - FiberPrep®
  - Fiberprobes®
  - Reservoir
  - Carriers

- Services & design sales
  - EasyScan®
  - EasyComb®
  - GMC On Demand

- Royalties
  - Distributors
  - Development partners
H1 / FY 2016: revenue from sales and cash position

<table>
<thead>
<tr>
<th>In € thousands – IFRS</th>
<th>FY (audited)</th>
<th>H1 (reviewed)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue from R&amp;D Collaboration with Quest Diagnostics</td>
<td>315</td>
<td>2,066</td>
</tr>
<tr>
<td>Sales of Products and Services</td>
<td>1,240</td>
<td>278</td>
</tr>
<tr>
<td>of which Life Science Research (LSR)</td>
<td>874</td>
<td>164</td>
</tr>
<tr>
<td>of which in-vitro diagnostics (IVD)</td>
<td>366</td>
<td>114</td>
</tr>
<tr>
<td>Total Revenue from Sales</td>
<td>1,555</td>
<td>2,345</td>
</tr>
</tbody>
</table>

- Full-year 2016 sales of products and services **up 346% to €1.2 million:**
  - strong growth momentum in both LSR and IVD markets in the second half of 2016
  - installed platform base x2

- Sales of products and services **up 141% to €0.7 million in H1 2017** thanks to strong trends in LSR market in Q2 after no sales of platform in Q1 as budgeted due to seasonal effect.

- Cash position as at June 30, 2017 of **€2.9 million** compared to €4.7 million as at March 31:
  - further potential funding of up to €8.5m in the form of convertible notes with warrants
  - given cost optimization measures implemented and 2016 tax credit to be cashed-in in Q3’17 for €1.4 million, available funding source offers more than 12 months visibility
Sales trend and 2017 outlook

2016

- New commercial structure set up
- FiberVision® platform installed based doubled
- Sales quadrupled vs 2015

2017 growth drivers

- Launch of replicome offering
- Worldwide unique position in FSHD reinforced
- US sales force presence increased
- Expansion in Asia (China)
- Partnerships to be considered

2017 target revenues: **DOUBLE** products & services sales
Several milestones in 2017

1. Replicome adoption by research & pharma labs
   - Adoption of the Replication Combing Assay by research & pharma labs for discovery and compounds optimization

2. HPV test (screening of cervical cancer risks given HPV integration)
   - Results of clinical study with PCS in Czech and IDAHO in France

3. Gene Editing safety tool offering
   - Establishment of the molecular combing GMC as safety tool for designing and executing gene editing

4. New platform and DNA extractors
   - Launch of new platform tailored for LSR individual labs

5. Partnership
   - Key partnership with a major Life Science player: global pharma or/and gene editing or/and biotech companies
Stock market information  (source: Euronext)

- 12-month high: €7.60 (Sept 26th, 2016)
- 12-month low: €2.6 (April 26th, 2017)
- Number of shares: 4,868,385
- Market Cap: €22.3m (June 5th, 2017)
- Average daily trading: 20,103 shares (over the last 12 months)

Shareholding structure  (As of 31.12.2016)

- Management, founders & employees: 0.3%
- Institut Pasteur: 3.6%
- Quest Diagnostic: 10.1%
- Vesalius Biocapital: 36.2%
- Free Float: 13.8%
- Treasury shares: 36.1%

Coverage
Thank you

Aaron Bensimon
Founder and CEO
Genomic Vision
a.bensimon@genomicvision.com
Tel +33 6 85 83 53 23

Frédéric Tarbouriech
CFO
Genomic Vision
f.tarbouriech@genomicvision.com
Tel +33 1 49 08 07 41